Program overview
Context
Indication: Metastatic Breast Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: AstraZeneca
Operational Burden Signal
Trastuzumab deruxtecan
Trastuzumab deruxtecan is flagged as operational burden signal because public records show timeline staleness, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 1/5
Timeline: 2/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 3/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT04538742 | https://clinicaltrials.gov/study/NCT06533826 | https://clinicaltrials.gov/study/NCT07428044
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT04538742 | Low Signal (ACTIVE_NOT_RECRUITING) | primary_completion_date_past_signal | long_recruitment_duration_signal | Low Signal | large_enrollment_target_signal | strict_eligibility_signal |
| NCT06533826 | Low Signal (RECRUITING) | long_recruitment_duration_signal | Low Signal | large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal |
| NCT07428044 | Low Signal (RECRUITING) | None | Low Signal | rare_population_signal | strict_eligibility_signal |